Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:01:29.935Z.
Calculation as of: 2026-10-06T18:01:29.935Z.
Quote observation: 2026-10-06T18:00:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 953d1456faf84e3d3f88a5480ffc5766df2e412b5fda6c1fb2fa7c75cf2e613b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$321.74M
Price/FCF Ratio
71.44
TTM Avg
796.59
3Y Avg
1526.97
5Y Avg
1526.97
Market Cap
$318.77M
Price/FCF Ratio
N/A
TTM Avg
114347.68
3Y Avg
114347.68
5Y Avg
114347.68
Market Cap
$302.90M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $322.03M | N/A | N/A | N/A | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.74M | 71.44 | 796.59 | 1526.97 | 1526.97 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $320.14M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $318.87M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $318.77M | N/A | 114347.68 | 114347.68 | 114347.68 |
| CapsoVision, Inc. (CV)vs › | $326.26M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $312.35M | N/A | N/A | N/A | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $302.90M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $302.32M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.76M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute